First National Bank of Omaha’s Teva Pharmaceuticals TEVA Stock Holding History

First National Bank of Omaha’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q3	–	Sell	-101,121	Closed	-$3.96K	–	398
2013 Q2	$3.96K	Buy	+101,121	New	+$3.94M	0.34%	100

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

First National Bank of Omaha's TEVA Position: Q3 2013 in Review

First National Bank of Omaha sold out of Teva Pharmaceuticals (TEVA) in Q3 2013, closing a stake of 101,121 shares — an estimated $3.96K sold.

First National Bank of Omaha first reported a position in TEVA in Q2 2013 and held it in 1 quarter. The position peaked at $3.96K in Q2 2013. 705 funds tracked by Wall St. Rank hold TEVA as of Q3 2013.

First National Bank of Omaha reported no remaining Teva Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
First National Bank of Omaha sold 101,121 Teva Pharmaceuticals shares in Q3 2013, an estimated $3.96K.
First National Bank of Omaha first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 1 quarter.
First National Bank of Omaha's Teva Pharmaceuticals position peaked at $3.96K in Q2 2013.
705 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2013.

Based on First National Bank of Omaha's 13F filing for Q3 2013, filed 12 Nov 2013.